Randall Kaye Net Worth

The estimated Net Worth of Randall Kaye is at least $548 Thousand dollars as of 23 December 2015. Randall Kaye owns over 1,000 units of Axsome Therapeutics Inc stock worth over $548,183 and over the last 9 years Randall sold AXSM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Randall Kaye AXSM stock SEC Form 4 insiders trading

Randall has made over 1 trades of the Axsome Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Randall bought 1,000 units of AXSM stock worth $9,030 on 23 December 2015.

The largest trade Randall's ever made was buying 1,000 units of Axsome Therapeutics Inc stock on 23 December 2015 worth over $9,030. On average, Randall trades about 500 units every 0 days since 2015. As of 23 December 2015 Randall still owns at least 6,022 units of Axsome Therapeutics Inc stock.

You can see the complete history of Randall Kaye stock trades at the bottom of the page.

What's Randall Kaye's mailing address?

Randall's mailing address filed with the SEC is 25 Broadway, New York, NY 10004, USA.

Insiders trading at Axsome Therapeutics Inc

Over the last 9 years, insiders at Axsome Therapeutics Inc have traded over $3,013,485 worth of Axsome Therapeutics Inc stock and bought 82,512 units worth $1,366,003 . The most active insiders traders include Roger Jeffs, Susan Mahony, and Mark Coleman. On average, Axsome Therapeutics Inc executives and independent directors trade stock every 114 days with the average trade being worth of $1,405,685. The most recent stock trade was executed by Mark E Saad on 11 September 2024, trading 11,016 units of AXSM stock currently worth $40,429.

What does Axsome Therapeutics Inc do?

axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.

Complete history of Randall Kaye stock trades at Axsome Therapeutics Inc

Axsome Therapeutics Inc executives and stock owners

Axsome Therapeutics Inc executives and other stock owners filed with the SEC include:

• Herriot Tabuteau,
  Chairman of the Board, President, Chief Executive Officer, Founder
• David Marek,
  Chief Commercial Officer
• Nick Pizzie,
  Chief Financial Officer
• Dr. Herriot Tabuteau M.D.,
  Founder, Chairman, CEO & Pres
• Mark L. Jacobson,
  COO & Sec.
• Nick Pizzie CPA, M.B.A.,
  Chief Financial Officer
• Roger Jeffs,
  Lead Independent Director
• Mark Saad,
  Independent Director
• Mark Coleman,
  Independent Director
• Amanda Jones,
  Senior Vice President - Clinical Research
• Cedric O'Gorman,
  Senior Vice President - Clinical Development and Medical Affairs
• Mark Jacobson,
  Chief Operating Officer
• Joseph Debrah-Afful CPA, M.B.A.,
  Director of Fin.
• Kevin Laliberte Pharm.D.,
  Exec. VP of Product Strategy
• Lori Englebert M.B.A.,
  Sr. VP of Commercial & Bus. Devel.
• Dr. Amanda Jones Pharm.D.,
  Sr. VP of Clinical Devel.
• Constance Ames,
  Vice President, Finance
• Myrtle S Potter,
  Director
• Randall Kaye,
  Chief Medical Officer
• Hunter R. Murdock,
  General Counsel
• John Golubieski,
  Chief Financial Officer
• Susan Mahony,